




NewalR&D

Ezrin Peptide Pharmaceuticals

**Products to treat infections &
chronic inflammatory diseases**


**Experimental volunteer treatment in Women:
Drug-Resistant Sex Infection and Long COVID**

Dr Rupert Holms, CEO, Inventor, Founder
drrupertholms@googlemail.com, rupertholms@newalrnd.com, www.newalrnd.com



Main Investment Attractions


- GLP1 peptide therapies prove pharmaceutical peptides are big business (USD \$100 billion global market growing at 20% p.a.)
- Human Ezrin Peptide pharmaceuticals are in patients: safe, effective and medically & commercially successful (fully de-risked)
- Human Ezrin Peptides can be delivered orally by solution spray inhalation, and by intra-vaginal wash
- Human Ezrin Peptides can cure any type of infection (viral, bacterial, fungal and protozoan)
- Human Ezrin Peptides can cure many types of inflammatory disease including Long COVID.
- Women are the main beneficiaries of ezrin peptides.



Immunology & Inflammation Therapy

Big Disease Problems, Big Markets

- The global immunology & inflammation treatment market is surging, forecast to grow to \$300 billion by 2035
- Sex infection is at an all-time high, respiratory infection is a huge problem, there are risks of new types of inflammatory viral respiratory diseases, long-COVID is still with us and super-bugs with anti-microbial-resistance are evolving
- Age related inflammatory disease is increasing as the population ages
- Long COVID: about 5% of the population, double prevalence in women



NewalR&D Team



Dr Rupert Holms Founder & CEO

Inventor of ezrin peptide pharmaceuticals, Founder of NewalR&D

Founded two successful biomedical businesses

Nearmedic in Moscow, a ~ £120 million immune-pharmaceutical business

hVIVO PLC in London, a ~£70 million drug screening and clinical trial business



Dr Phillip Hay Chief Medical Officer

Consultant in Sexual Health


Guy's and St Thomas' NHS Foundation Trust, London

Specialist in the sexual health of women




Dr John Abeles Chairman


Biotech founder and financier based in New York, responsible for multiple start-ups and successful exits via IPOs or corporate acquisitions



The Ezrin Peptide Solution




- Ezrin peptides are SAFE and already in human use
 - IMPROVE natural adaptive immune amplification
 - SUPPRESS chronic expression of inflammatory cytokines
 - TREAT age-related inflammatory diseases
 - Ezrin peptides can treat multiple types of infectious agents: Viral, Bacterial, Fungal or Protozoan
 - Ezrin peptide pharmaceuticals are protected by patents
- Ezrin peptides are profitable & affordable therapies for patients**
A fast-to-market human health product under development.



Development Road Map

- £ 5 million new capital for lead peptide selections, peptide synthesis, pre-clinical mechanism of action, kinetics and safety, Generation-4 ezrin peptide knowhow development, new patent protection and human phase I/II clinical trials
- Additional £ 10 million new capital for phase II and phase III clinical trials and product registration in EU / UK / USA / China
- Ezrin peptides are active at 1mg to 5mg per day per patient
- Preferred drug delivery: peptide solution spray inhalation
- Price Point: £100 for course of infection treatment
- Marketing: Prescription to OTC high volume mass marketing
- Different ezrin peptides tailored for age related inflammatory disease and Long COVID at higher price points
- Simple and cheap contract manufacturing of short peptides



Newal R&D

Chance of a BIG WIN

- Ezrin peptide efficacy in chronic inflammatory diseases:
- Inflammatory viral infections (Dengue, Chikungunya & Zika)
- Inflammatory spine diseases (Ankylosing Spondylitis)
- Inflammatory bowel diseases (Ulcerative Colitis)
- Inflammatory heart diseases (Myocarditis)
- Inflammatory brain diseases (Long COVID & Dementia)
- Ezrin peptides may stimulate healthy aging, health-span extension and longevity
- A chance of a \$ billion+ exit for investors in NewalR&D



New Capital for NewalR&D

**Raising £5 million Series-A
Private Placing of Ordinary Shares
Pre-Money Value £10 million**

**Targeted IPO Value of £100+ million
Targeted Acquisition Value of £1000+ million**

THANK YOU FOR YOUR ATTENTION

drrupertholms@googlemail.com, rupertholms@newalrnd.com, www.newalrnd.com

+44 780 3042576